Company: XERI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003761
Chunk: 31

Company: XERIANT, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part II, Item 8
Chunk 31
---
 and $147,259 for the nine months ended March 31 2025 and 2024, respectively, a decrease of $90,459. The primary reason for the decrease was increased testing and related travel costs in the prior period.

Other Income (Expenses)  

Total other expenses consist of amortization of debt discount, interest expense related to convertible notes, loss and gain on extinguishment of debt and change in fair value of the convertible bridge loans. Total other expenses were $166,463 for the nine months ended March 31, 2025, compared to $921,206 for the nine months ended March 31, 2024. The decrease of $754,743 was primarily due to recording the Auctus default interest in the prior period.

Net loss

Total net loss was $1,319,759 for the nine months ended March 31, 2025, compared to $1,933,003 for the nine months ended March 31, 2024, a decrease of $613,244. The decrease of $613,244 was primarily due to recording the Auctus default interest in the prior period.

Three months ended March 31, 2025 Results of Operations Compared with three months ended March 31, 2024

  For the three months ended     March 31,      2025  2024  $            Operating expenses:         Consulting and advisory fees $141,600  $39,650  $101,950 Related party consulting fees  113,500   89,500   24,000 General and administrative expenses  102,087   68,309   33,778 Professional fees  71,507   87,981   (16,474)Research and development expense  30,224   67,524   (37,300)Total operating expenses  458,918   352,964   105,954 Operating loss  (458,918)  (352,964)  (105,954)             Other expenses:            Amortization of debt discount  (5,197)  (2,569)  (2,628)Interest expense  (66,153)  (28,563)  (37,590)Loss on extinguishment of debt  -   -